Correction to: Development of a control strategy for a defluorinated analogue in the manufacturing process of casopitant mesylate (Organic Process Research and Development (2010) 14 (832-839) DOI: 10.1021/op1000836);Development of a control strategy for a defluorinated analogue in the manufacturing process of casopitant mesylate

Organic Process Research and Development

Volumn 14, Issue 4, 2010, Pages 832-839

  Bravo, Fernando ^a   Cimarosti, Zadeo ^a   Tinazzi, Francesco ^a   Castoldi, Damiano ^a   Stonestreet, Paul ^b   Galgano, Annalisa ^a   Westerduin, Pieter ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; PLANNING; QUALITY ASSURANCE; RISK ANALYSIS; RISK ASSESSMENT;

CENTRAL NERVOUS SYSTEMS; CONTROL STRATEGIES; GLAXO SMITHKLINE; MANUFACTURING PROCESS; PHASE DEVELOPMENT; PROCESS DEVELOPMENT; PROCESS UNDERSTANDING; QUALITY BY DESIGNS;

QUALITY CONTROL;

EID: 77955345182     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/acs.oprd.7b00226     Document Type: Erratum

References (22)

1. Pharmaceutical cGMPs for the 21st century- A risk based approach (initiative launched in 2002).
2. We have recently published an application of the QbD principles to the control of genotoxin impurities
3. Cimarosti, Z.; Bravo, F.; Stonestreet, P.; Tinazzi, F.; Vecchi, O.; Camurri, G. Org. Proc. Res. Dev. [Online early access]. DOI: 10.1021/op900242x. Published Online: Nov 6, 2009.
4. ICH Q8 Pharmaceutical Development.
5. ICH Q9 Quality Risk Management.
6. ICH Q10 Pharmaceutical Quality System.
7. Dams, R.; Bernab, E.; Nicoletti, A.; Loda, C.; Martini, L.; Papini, D.. Quantitation of Defluorinated Analogue of Casopitant Mesylate by Normal Phase Liquid Chromatography-Mass Spectrometry. Manuscript in preparation.
8. ICH Q6a Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
9. Activation of the strong C-F bond is a topic of growing interest, and different metals have been reported to perform this transformation. From a bibliographic search, it would seem more likely that Rh is the responsible due to a higher number of hits, although both Rh and Pd-based catalyst have been reported to conduct the defluorination reaction. Indeed, there is a relatively higher number of examples of defluorination of fluorobenzenes in the presence of Rh, in particular employing homogeneous Rh complexes; see for instance
10. Aizenberg, M.; Milstein, D. Science 1994, 265, 359-361
11. Aizenberg, M.; Milstein, D. J. Am. Chem. Soc. 1995, 117, 8674-8675
12. Braun, T.; Noveski, D.; Ahijado, M.; Wehmeier, F. Dalton Trans. 2007, 3820-3825
13. Noveski, D.; Braun, T.; Stammler, A.; Stammler, H.-G. Dalton Trans. 2004, 4106-4119
14. 3)
15. 2). In less extent, Pd-based catalyst have also been successfully employed. Ukisu, Y.; Miyadera, T. J. Mol. Catal. A: Chem. 1997, 125, 135-142 (heterogeneous Pd/C)
16. Aramendia, M. A.; Borau, V.; Garcia, I. M.; Jimenez, C.; Marinas, A.; Marinas, J. M.; Urbano, F. J. C. R. Acad. Sci. Paris, Ser. IIC, Chim. 2000, 3, 465-470 In contrast with the literature precedents, the information collected by catalyst suppliers suggests the use of Pd/C for defluorination, see: Handbook of Pharmaceutical Catalysis; Johnson Matthey Catalysts: Royston, U.K., 2009, p 37.
17. The y-axis of the graph is defined as cumulative probability, a measure of the % of individuals expected to fall below a given level. The x-axis is defined as a measure of the magnitude of the effect.
18. Alvaro, G.; Di Fabio, R.; Maragni, P.; Tampieri, M.; Tranquillini, M. E. PCT Int. Appl. WO 2002/032867, 2002
19. Chem. Abstr. 2002, 136, 325568.
20. Bientinesi, I.; Cimarosti, Z.; Guercio, G.; Leroi, C.; Perboni, A. PCT Int. Appl. WO 2007/048642, 2007
21. Chem. Abstr. 2007, 146, 461973.
22. Guercio, G.; Bacchi, S.; Perboni, A.; Leroi, C.; Tinazzi, F.; Bientinesi, I.; Hourdin, M.; Goodyear, M.; Curti, S.; Provera, S.; Cimarosti, Z. Org. Process Res. Dev. 2009, 13, 1100-1110